

Ciro Gallo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6194786/publications.pdf>

Version: 2024-02-01

164
papers

12,810
citations

31976

53
h-index

24258

110
g-index

168
all docs

168
docs citations

168
times ranked

12780
citing authors

#	ARTICLE	IF	CITATIONS
1	Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. <i>Lancet Oncology</i> , The, 2022, 23, 382-392.	10.7	107
2	Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1086-1097.	1.1	25
3	A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system. <i>Supportive Care in Cancer</i> , 2021, 29, 3219-3233.	2.2	12
4	Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial. <i>European Journal of Cancer</i> , 2021, 148, 422-429.	2.8	8
5	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. <i>BMC Cancer</i> , 2021, 21, 549.	2.6	10
6	Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2118475.	5.9	16
7	The opportunity of patient-journey studies for academic clinical research in oncology. <i>BMJ Open</i> , 2021, 11, e052871.	1.9	2
8	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. <i>BMJ Open</i> , 2021, 11, e049128.	1.9	12
9	Prospective validation of the International Warfarin Pharmacogenetics Consortium algorithm in high-risk elderly people (VIALE study). <i>Pharmacogenomics Journal</i> , 2020, 20, 451-461.	2.0	1
10	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020, 18, 405.	4.4	98
11	A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCID-19 trial): Statistical analysis plan. <i>Contemporary Clinical Trials Communications</i> , 2020, 20, 100665.	1.1	13
12	TOCID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. <i>Contemporary Clinical Trials</i> , 2020, 98, 106165.	1.8	9
13	Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All Approach. <i>Journal of Oncology Practice</i> , 2019, 15, 460-461.	2.5	7
14	Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics. <i>Journal of Nephrology</i> , 2019, 32, 429-435.	2.0	5
15	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBEO phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 118, 178-186.	2.8	39
16	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. <i>Lung Cancer</i> , 2019, 133, 62-68.	2.0	5
17	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , 2019, 154, 83-88.	1.4	9
18	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 535-540.	1.4	19

#	ARTICLE	IF	CITATIONS
19	Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol. <i>BMJ Open</i> , 2019, 9, e031485.	1.9	14
20	Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 1189-1194.	1.2	8
21	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
22	Predictivity of clinical, laboratory and imaging findings in diagnostic definition of palpable thyroid nodules. A multicenter prospective study. <i>Endocrine</i> , 2018, 61, 43-50.	2.3	6
23	Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2585-2592.	1.6	42
24	Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5506-5506.	1.6	55
25	A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients. <i>Lung Cancer</i> , 2017, 108, 15-21.	2.0	10
26	Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies. <i>Annals of Oncology</i> , 2017, 28, vi2.	1.2	3
27	Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3347-3353.	1.6	66
28	Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 515-515.	1.6	3
29	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 57528-57536.	1.8	7
30	A prognostic index for patients within the intermediate stage of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 592-598.	1.6	1
31	The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. <i>Annals of Oncology</i> , 2016, 27, 2224-2229.	1.2	103
32	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 461-465.	2.6	37
33	Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant <i>Acinetobacter baumannii</i> infections. <i>Clinical Microbiology and Infection</i> , 2016, 22, 984-989.	6.0	30
34	A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization) Tj ETQq0 0gBT /Overlock 10	1.6	1
35	Treatment withdrawal in relapsing/remitting multiple sclerosis: a retrospective cohort study. <i>European Journal of Neurology</i> , 2016, 23, 489-493.	3.3	8
36	The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5505-5505.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. <i>Oncotarget</i> , 2016, 7, 72654-72661.	1.8	15
38	Reply to P. Baldo et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 2826-2826.	1.6	0
39	Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 910-915.	1.6	361
40	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 561-568.	10.7	141
41	Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. <i>Annals of Oncology</i> , 2015, 26, 675-682.	1.2	56
42	MITO (Multicentre Italian Trials in Ovarian cancer): CERV 2 trialâ€”A randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5520-5520.	1.6	0
43	Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum) Tj ETQq1 1 0z784314 rgBT /Oved		
44	Prognostic value of circulating tumor cellsâ€™™ reduction in patients with extensive small-cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 314-319.	2.0	56
45	Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Nonâ€”Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 166-170.	2.6	25
46	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405.	10.7	327
47	Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 1254-1262.	10.7	95
48	Epidemiological study on behavioural and emotional problems in developmental age: prevalence in a sample of Italian children, based on parent and teacher reports. <i>Italian Journal of Pediatrics</i> , 2014, 40, 19.	2.6	28
49	Carboplatin plus paclitaxel scheduling for advanced ovarian cancer â€” Authors' reply. <i>Lancet Oncology</i> , The, 2014, 15, e250-e251.	10.7	3
50	MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5503-5503.	1.6	9
51	Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-Î± in advanced malignant melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 38.	4.4	21
52	Health effects associated with the disposal of solid waste in landfills and incinerators in populations living in surrounding areas: a systematic review. <i>International Journal of Public Health</i> , 2013, 58, 725-735.	2.3	79
53	Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant <i>Acinetobacter baumannii</i> : A Multicenter, Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2013, 57, 349-358.	5.8	322
54	Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study. <i>Lung Cancer</i> , 2013, 81, 77-83.	2.0	51

#	ARTICLE	IF	CITATIONS
55	Early PET/CT Scan Is More Effective Than RECIST in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2062-2069.	5.0	51
56	Reply to V. Lorusso et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 289-290.	1.6	0
57	Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBEO study. <i>Annals of Oncology</i> , 2012, 23, 2027-2033.	1.2	22
58	The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. <i>Kidney International</i> , 2012, 82, 482-488.	5.2	75
59	Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2012, 30, 1692-1698.	1.6	422
60	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1830-1844.	1.1	23
61	Phase III Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial. <i>Journal of Thoracic Oncology</i> , 2012, 7, 233-242.	1.1	5
62	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3002-3011.	1.6	229
63	Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. <i>Lung Cancer</i> , 2012, 76, 457-464.	2.0	32
64	Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients. <i>Scientific World Journal</i> , The, 2012, 2012, 1-7.	2.1	19
65	High cardiovascular risk in patients with Type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2269-2274.	0.7	60
66	Pulse wave velocity is associated with muscle mass decline: Health ABC study. <i>Age</i> , 2012, 34, 469-478.	3.0	92
67	Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. <i>BMC Cancer</i> , 2011, 11, 75.	2.6	13
68	Prognosis of CKD Patients Receiving Outpatient Nephrology Care in Italy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2421-2428.	4.5	88
69	Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3628-3635.	1.6	182
70	Time Spent for Activation of Non-Profit Studies in Oncology in Italy. <i>PLoS ONE</i> , 2010, 5, e11864.	2.5	3
71	Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1645-1651.	1.6	279
72	Reply to P.E. Lønning et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e103-e104.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. <i>Lung Cancer</i> , 2010, 67, 86-92.	2.0	23
74	Methodological aspects of lung cancer clinical trials in the era of targeted agents. <i>Lung Cancer</i> , 2010, 67, 127-135.	2.0	30
75	Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. <i>European Journal of Cancer</i> , 2010, 46, 735-743.	2.8	71
76	Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey. <i>Tumori</i> , 2009, 95, 647-651.	1.1	18
77	Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1836-1843.	1.6	166
78	Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBEO Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3192-3197.	1.6	71
79	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1021-1027.	2.3	8
80	Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2009, 63, 251-258.	2.0	31
81	A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 229-236.	4.4	72
82	Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. <i>Cancer</i> , 2008, 113, 65-71.	4.1	45
83	Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 171-180.	4.4	23
84	An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non-Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial. <i>Clinical Lung Cancer</i> , 2008, 9, 235-238.	2.6	32
85	Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression. <i>American Journal of Kidney Diseases</i> , 2008, 52, 475-485.	1.9	76
86	Re: Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1557-1557.	6.3	14
87	Endocrine Effects of Adjuvant Letrozole + Triptorelin Compared With Tamoxifen + Triptorelin in Premenopausal Patients With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 264-270.	1.6	36
88	Re: Visualizing Length of Survival in Time-to-Event Studies: A Complement to Kaplan-Meier Plots. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1188-1188.	6.3	0
89	Is human hepatocellular carcinoma a hormone-responsive tumor?. <i>World Journal of Gastroenterology</i> , 2008, 14, 1682.	3.3	46
90	Cisplatin Plus Gemcitabine or Vinorelbine for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The MILES-2P Studies. <i>Journal of Clinical Oncology</i> , 2007, 25, 4663-4669.	1.6	77

#	ARTICLE	IF	CITATIONS
91	A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. <i>British Journal of Cancer</i> , 2007, 96, 1639-1643.	6.4	28
92	First-Line Chemotherapy for HER-2â€“Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment. <i>Oncologist</i> , 2007, 12, 1288-1298.	3.7	11
93	Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1377-1382.	1.6	110
94	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEMcitabine-COxib in NSCLC (GECO) study. <i>Lancet Oncology</i> , The, 2007, 8, 500-512.	10.7	89
95	Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 243-249.	4.4	48
96	Hormonal Treatment of Human Hepatocellular Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 252-261.	3.8	33
97	Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2006, 6, 196.	2.6	18
98	Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 114-115.	4.3	10
99	Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. <i>British Journal of Cancer</i> , 2006, 94, 1233-1236.	6.4	27
100	Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy. <i>Cancer</i> , 2005, 104, 1362-1371.	4.1	207
101	Cost of Insurance Policies for Investigator-Initiated Cancer Clinical Trials in Italy. <i>Tumori</i> , 2005, 91, 373-379.	1.1	4
102	Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6865-6872.	1.6	452
103	Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. <i>British Journal of Cancer</i> , 2005, 93, 896-904.	6.4	11
104	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. <i>Lancet Oncology</i> , The, 2005, 6, 669-677.	10.7	197
105	Prognostic Value of CD40 in Adult Soft Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2004, 10, 2824-2831.	7.0	12
106	Outcome of Patients With a Performance Status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). <i>Journal of Clinical Oncology</i> , 2004, 22, 5018-5020.	1.6	22
107	Insurance for independent cancer trials. <i>Annals of Oncology</i> , 2004, 15, 1722-1723.	1.2	3
108	Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2635-2642.	1.6	149

#	ARTICLE	IF	CITATIONS
109	Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2004, 90, 2288-2296.	6.4	111
110	A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. <i>British Journal of Cancer</i> , 2004, 91, 1996-2004.	6.4	158
111	Clinical trial design in oncology. <i>Lancet Oncology</i> , The, 2004, 5, 759-763.	10.7	4
112	Clinical trial design in oncology: statistical power. <i>Lancet Oncology</i> , The, 2004, 5, 760-1.	10.7	3
113	Long-term stability of skeletal Class III patients treated with splints, Class III elastics, and chin cup. <i>American Journal of Orthodontics and Dentofacial Orthopedics</i> , 2003, 123, 423-434.	1.7	51
114	Supportive care in patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2003, 89, 1013-1021.	6.4	27
115	Statistical design in phase II clinical trials and its application in breast cancer. <i>Lancet Oncology</i> , The, 2003, 4, 305-311.	10.7	25
116	Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2003, 95, 362-372.	6.3	768
117	Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction. <i>Journal of Clinical Oncology</i> , 2003, 21, 767-773.	1.6	91
118	Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 3025-3034.	1.6	232
119	Hepatic Resection and Percutaneous Ethanol Injection as Treatments of Small Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 63-67.	2.2	71
120	First-Line Chemotherapy With Fluorouracil and Folinic Acid for Advanced Colorectal Cancer in Elderly Patients. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 228-233.	2.2	31
121	Chemotherapy in the Elderly. <i>New England Journal of Medicine</i> , 2002, 346, 622-623.	27.0	4
122	Re: Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1029-1030.	6.3	48
123	Survey of Modalities of Toxicity Assessment and Reporting in Noncomparative Prospective Studies of Chemotherapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 52-57.	1.6	7
124	Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial. <i>Current Pharmaceutical Design</i> , 2002, 8, 1013-1019.	1.9	50
125	Risk of warfarin during pregnancy with mechanical valve prostheses. <i>Obstetrics and Gynecology</i> , 2002, 99, 35-40.	2.4	163
126	Risk of warfarin during pregnancy with mechanical valve prostheses. <i>Obstetrics and Gynecology</i> , 2002, 100, 1041.	2.4	1

#	ARTICLE	IF	CITATIONS
127	Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. <i>Lung Cancer</i> , 2002, 36, 327-332.	2.0	20
128	Survey of Modalities of Toxicity Assessment and Reporting in Noncomparative Prospective Studies of Chemotherapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 52-57.	1.6	8
129	Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients. <i>Lung Cancer</i> , 2001, 31, 277-284.	2.0	123
130	Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. <i>British Journal of Cancer</i> , 2001, 84, 38-41.	6.4	14
131	Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. <i>Gut</i> , 2001, 48, 28-33.	12.1	117
132	Quality of life in elderly cancer patients. <i>Annals of Oncology</i> , 2001, 12, S49-S52.	1.2	31
133	Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. <i>Hepatology</i> , 2000, 31, 840-845.	7.3	546
134	Randomized, controlled trial to compare the J-pouch and W-pouch configurations for ulcerative colitis in the maturation period. <i>Diseases of the Colon and Rectum</i> , 2000, 43, 615-620.	1.3	42
135	Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. <i>British Journal of Cancer</i> , 2000, 83, 707-714.	6.4	60
136	Phase II Study of Cisplatin and Vinorelbine as First-Line Chemotherapy in Patients With Carcinoma of the Uterine Cervix. <i>Journal of Clinical Oncology</i> , 1999, 17, 756-756.	1.6	65
137	Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 66-72.	6.3	901
138	A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. <i>Hepatology</i> , 1998, 28, 751-755.	7.3	1,271
139	Morbidity patterns in aged population in southern Italy. A survey sampling. <i>Archives of Gerontology and Geriatrics</i> , 1998, 26, 201-213.	3.0	38
140	Tamoxifen in hepatocellular carcinoma. <i>Lancet, The</i> , 1998, 352, 820.	13.7	5
141	Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. <i>Lancet, The</i> , 1998, 352, 17-20.	13.7	210
142	Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit?. <i>European Journal of Cancer</i> , 1998, 34, 25-32.	2.8	22
143	Immunological Phenotype Analysis of Patients with Fanconiâ€™s Anaemia and Their Family Members. <i>Acta Haematologica</i> , 1998, 100, 39-43.	1.4	16
144	Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. <i>Gruppo Oncologico Centro-Sud-Isole.. Journal of Clinical Oncology</i> , 1998, 16, 1414-1419.	1.6	25

#	ARTICLE	IF	CITATIONS
145	Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. <i>European Journal of Cancer</i> , 1997, 33, 392-397.	2.8	101
146	Selecting high-risk early breast cancer patients: What to add to the number of metastatic nodes?. <i>European Journal of Cancer</i> , 1996, 32, 41-46.	2.8	10
147	c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2702-2708.	1.6	380
148	Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. <i>Annals of Oncology</i> , 1996, 7, 821-826.	1.2	32
149	A predictive index of axillary nodal involvement in operable breast cancer. <i>British Journal of Cancer</i> , 1996, 73, 1241-1247.	6.4	41
150	Prognostic Significance of Necrosis, Elastosis, Fibrosis and Inflammatory Cell Reaction in Operable Breast Cancer. <i>Oncology</i> , 1995, 52, 272-277.	1.9	40
151	The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. <i>Cancer</i> , 1995, 76, 1772-1778.	4.1	162
152	CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). <i>British Journal of Cancer</i> , 1995, 71, 1283-1287.	6.4	28
153	The First Breast Cancer Screening Program in Southern Italy: Preliminary Results from Three Municipalities of the Naples Province. <i>Tumori</i> , 1995, 81, 7-12.	1.1	8
154	Phase II study of intensive CEV (Carboplatin, Epirubicin and VP-16) Plus G-CSF (granulocyte-colony) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2424-2426.	2.8	5
155	Informed versus randomised consent to clinical trials. <i>Lancet, The</i> , 1995, 346, 1060-1064.	13.7	61
156	PROGNOSTIC-SIGNIFICANCE OF MULTIFOCALITY IN PRIMARY BREAST-CANCER. <i>Oncology Reports</i> , 1994, 1, 1045-8.	2.6	0
157	Endocrine Factors in the Outcome of Systemic Adjuvant Therapy of Early Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 330-338.	3.8	2
158	Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. <i>British Journal of Cancer</i> , 1991, 63, 799-803.	6.4	101
159	Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study. <i>British Journal of Cancer</i> , 1990, 62, 643-646.	6.4	23
160	Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 1990, 16, 111-117.	2.5	11
161	ADJUVANT THERAPY WITH TAMOXIFEN IN OPERABLE BREAST CANCER. <i>Lancet, The</i> , 1988, 332, 1095-1099.	13.7	45
162	Immunosuppressive Therapy of HBsAg-Positive Chronic Active Hepatitis in Childhood. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1988, 7, 17-21.	1.8	1

#	ARTICLE	IF	CITATIONS
163	Prognostic Significance of Circulating Immune Complexes in a Long-Term Follow-Up of Breast Cancer Patients. <i>Oncology</i> , 1988, 45, 337-343.	1.9	1
164	Etiological, clinical and laboratory data of post-transfusion hepatitis: A retrospective study of 379 cases from 53 italian hospitals. <i>Infection</i> , 1987, 15, 111-114.	4.7	5